MethylGene Inc. (MYG) - Financial and Strategic SWOT Analysis Review

Document Sample
MethylGene Inc. (MYG) - Financial and Strategic SWOT Analysis Review Powered By Docstoc
					        MethylGene Inc. (MYG) - Financial and Strategic SWOT Analysis Review
        Reference Code: GDPH61725FSA                                                                                          Publication Date: APR 2013

          7220 Frederick-Banting, Suite 200                  Phone              +1 514 3373333                  Revenue          NA
          Montreal, QC                                       Fax                +1 514 3370550                  Net Profit       -9.73 (million CAD)
          H4S 2A1                                            Website            www.methylgene.com              Employees        NA
                                                                                MYG [Toronto         Stock                       Pharmaceuticals           &
          Canada                                             Exchange                                           Industry
                                                                                Exchange]                                        Healthcare

       Company Overview
       MethylGene Inc. (MethylGene) is a development stage biopharmaceutical company. It discovers, develops and markets novel
       therapeutics for the treatment of cancer and infectious diseases. The company's product pipeline consists of MGCD290 (Hos2
       fungal inhibitor), MGCD265 (Met/VEGF kinase inhibitor), MG516 (Eph/Met kinase inhibitor) and MG96077 (beta-la ctamase
       inhibitor). It develops these products for the treatment of cancer, nuerodegenration, fungal infections, ocular diseases and
       bacterial infections. MethylGene's partnered products include mocetinostat (HDAC inhibitor), EVP-0334 (HDAC inhibitor) and
       Kinase inhibitors.
       Key Executives                                                                SWOT Analysis
                      Name                                 Title                      MethylGene Inc., SWOT Analysis
         Martin Godbout, Ph.D.               Chairman                                 Strengths                              Weaknesses
         Charles M. Baum, M.D., Chief Executive Officer
                                                                                      Sturdy Research and                    Weak Financial Performance
         Ph.D.
                                                                                      Development
         Henry J. Fuchs, M.D.                Director                                                                        Lack of Commercial Products
                                                                                      Target-Specific Drugs
         Peggy Mulligan                      Director
         Rodney Lappe, Ph.D.                 Director
        Source: Annual Report, Company Website, Primary and Secondary
                                                                                      Opportunities                          Threats
        Research, GlobalData
                                                                                      Biotech Focus                          Tightening of the FDA’s
       Share Data                                                                                                            Regulatory Oversight
                                                                                      Collaborative Agreements
         MethylGene Inc.
                                                                                                                             Fierce Competition
        Share Price (CAD) as on 22-Apr-                                  0.11
        2013
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
        EPS (CAD)                                                       -0.04        GlobalData
        Market Cap (million CAD)                                           33
        Enterprise Value (million CAD)                                     28
        Shares Outstanding (million)                                     318
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData

       Financial Performance                                                         Recent Developments
                                                                                      Mar 14, 2013         MethylGene Appoints Mark Gergen As CFO
                                                                                      Mar 13, 2013         MethylGene Reports 2012 Results
                                                                                      Feb 19, 2013         MethylGene Appoints Mark Gergen As COO
                                                                                      Nov 14, 2012         MethylGene Reports Q3 2012 Results
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData




       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData




MethylGene Inc. (MYG) - Financial and Strategic SWOT Analysis                                                                  Reference Code: GDPH61725FSA
Review
Source : www.globalcompanyintelligence.com                                                                                                                     Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 4
          List of Figures ................................................................................................................................................................................. 4
       Section 1 - About the Company.......................................................................................................................................................... 5
       MethylGene Inc. - Key Facts .............................................................................................................................................................. 5
       MethylGene Inc. - Key Employees ..................................................................................................................................................... 6
       MethylGene Inc. - Key Employee Biographies ................................................................................................................................... 7
       MethylGene Inc. - Major Products and Services ................................................................................................................................ 8
       MethylGene Inc. - Pharmaceutical Pipeline Products Data ................................................................................................................ 9
          MethylGene Inc., Pipeline Products by Therapy Area .................................................................................................................... 9
          MethylGene Inc., Pipeline Products by Development Phase ........................................................................................................ 10
       MethylGene Inc. - History ................................................................................................................................................................. 12
       MethylGene Inc. - Company Statement ........................................................................................................................................... 15
       MethylGene Inc. - Locations And Subsidiaries ................................................................................................................................. 19
          Head Office ................................................................................................................................................................................... 19
          Other Locations & Subsidiaries ..................................................................................................................................................... 19
       Section 2 – Company Analysis ......................................................................................................................................................... 20
       MethylGene Inc. - Business Description ........................................................................................................................................... 20
       MethylGene Inc. - SWOT Analysis ................................................................................................................................................... 21
          SWOT Analysis - Overview........................................................................................................................................................... 21
          MethylGene Inc. - Strengths ......................................................................................................................................................... 21
             Strength - Sturdy Research and Development .......................................................................................................................... 21
             Strength - Target-Specific Drugs ............................................................................................................................................... 21
             Strength - First in Class Drug Candidate ................................................................................................................................... 21
          MethylGene Inc. - Weaknesses .................................................................................................................................................... 21
             Weakness - Weak Financial Performance ................................................................................................................................ 21
             Weakness - Lack of Commercial Products................................................................................................................................ 22
          MethylGene Inc. - Opportunities ................................................................................................................................................... 22
             Opportunity - Biotech Focus ...................................................................................................................................................... 22
             Opportunity - Collaborative Agreements ................................................................................................................................... 22
             Opportunity - Market Potential: Cancer Therapeutics................................................................................................................ 22
          MethylGene Inc. - Threats ............................................................................................................................................................ 23
             Threat - Tightening of the FDA’s Regulatory Oversight ............................................................................................................. 23
             Threat - Fierce Competition....................................................................................................................................................... 23
             Threat - Uncertain R&D outcomes ............................................................................................................................................ 23
       MethylGene Inc. - Key Competitors.................................................................................................................................................. 24
       Section 3 – Company Financial Ratios ............................................................................................................................................. 25
       Financial Ratios - Capital Market Ratios........................................................................................................................................... 25
       Financial Ratios - Annual Ratios ...................................................................................................................................................... 25
       Performance Chart ........................................................................................................................................................................... 27
       Financial Performance...................................................................................................................................................................... 27
       Financial Ratios - Interim Ratios....................................................................................................................................................... 28
       Financial Ratios - Ratio Charts ......................................................................................................................................................... 29
       Section 4 – Company’s Lifesciences Financial Deals and Alliances ................................................................................................ 30
          MethylGene Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013 .................................................................. 30


MethylGene Inc. (MYG) - Financial and Strategic SWOT Analysis                                                                                                  Reference Code: GDPH61725FSA
Review
Source : www.globalcompanyintelligence.com                                                                                                                                                                Page 2
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
          MethylGene Inc., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013 ................................................................. 31
       MethylGene Inc., Recent Deals Summary........................................................................................................................................ 32
       Section 5 – Company’s Recent Developments ................................................................................................................................ 33
          MethylGene Inc., Recent Developments....................................................................................................................................... 33
             Mar 14, 2013: MethylGene Appoints Mark Gergen As CFO ..................................................................................................... 33
             Mar 13, 2013: MethylGene Reports 2012 Results .................................................................................................................... 33
             Feb 19, 2013: MethylGene Appoints Mark Gergen As COO ..................................................................................................... 34
             Nov 14, 2012: MethylGene Reports Q3 2012 Results............................................................................................................... 35
             Nov 12, 2012: MethylGene Appoints Charles Baum As CEO ................................................................................................... 36
             Sep 24, 2012: MethylGene Announces Senior Management Changes .................................................................................... 36
             Aug 02, 2012: MethylGene Reports Q2 2012 Results............................................................................................................... 36
             May 14, 2012: MethylGene Reports Q1 2012 Results .............................................................................................................. 36
             Mar 19, 2012: MethylGene Appoints Peggy Mulligan To Board ................................................................................................ 37
             Mar 15, 2012: MethylGene Reports Q4 2011 Results ....................................
				
DOCUMENT INFO
Description: MethylGene Inc. (MYG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better. The profile contains critical company information including: - Business description – A detailed description of the company’s operations and business divisions. - Corporate strategy – Analyst’s summarization of the company’s business strategy. - SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats. - Company history – Progression of key events associated with the company. - Major products and services – A list of major products, services and brands of the company. - Key competitors – A list of key competitors to the company. - Key employees – A list of the key executives of the company. - Executive biographies – A brief summary of the executives’ employment history. - Key operational heads – A list of personnel heading key departments/functions. - Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company. - Key manufacturing facilities – A list of key manufacturing facilities of the company. - Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history. - Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history. Highlights MethylGene Inc. (MethylGene) is a development stage biopharmaceutical company. It discovers, develops
BUY THIS DOCUMENT NOW PRICE: $125 100% MONEY BACK GUARANTEED
PARTNER GlobalData
GlobalData is an industry analysis specialist, providing business information products and services. GlobalData’s highly qualified team of analysts, researchers, and solution consultants use proprietary data sources, tools and techniques to gather, analyze and represent the latest and the most reliable information essential for a business to sustain a competitive edge. GlobalData is a UK-based company with presence across North America, Europe and Asia Pacific and has a broad product offering that ranges from interactive databases, reports and custom solutions. It is a comprehensive source of insights and analysis with coverage across the oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries. GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries. Sectors and Geographies Covered GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. Research Methodology With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries.